

SynBalance® MetSyn Take care of you !

Probiotic complex targeting metabolic syndrome (LP - PBS067, LA – LA001, LR – PBS072)

Improvement of anthropometric factors & quality of life Reduction of systemic inflammation and oxidative stress

Gut health symptoms improvement

Typical dosage: 6B CFU/day (2B CFU/strain) – minimum 60 days treatment



www.roelmihpc.com

SynBalance® MetSyn

In-vitro influence on carbohydrates and lipids metabolism

 $\Delta \alpha$ -amylase, α -glucosidase are the enzymes involved in the digestion-absorption of carbohydrates and hydrolyzation of oligosaccharides to release glucose. Modulation of lipolysis and cholesterol biosynthesis as biological markers of hyperlipidemia and hypercholesterolemia.

a-amilase

Q SynBalance[®] MetSyn is effective in inhibiting the enzymatic activity and the corresponding starch digestion, modulating the carbohydrate digestion and reducing the absorption of sugars.

• SynBalance[®] MetSyn improves the exploitation of lipid mass and helps keeping under control the cholesterol blood level.



lipase

α-glucosidase

Clinical modulation of metabolic profile

☆ RDBPC clinical trial involving 60 subjects (randomized as 30 active/ 30 placebo), 65-80 years old, with metabolic syndrome diagnosis. Checks are scheduled at T0 and T60. QoL questionnaires collected after wash-out.

Q All dyslipidemic markers were improved in MetSyn group during the treatment without changing the dietary habits: especially TG and LDL-C were statistically reduced and HDL-C increased with respect to placebo.

Q Also fasting plasma insulin (FPI) diminished thanks to a more efficient use of endogenous insulin and an enhanced carbohydrates metabolism.

Improvement of obesity markers

Q Waist circumference in overweight people was reduced by 4 cm in the active group together with visceral adipose index (-10%).

Q In another study, typical symptoms correlated to GI dysfunction in overweigh and obese people such as constipation and bloating, were also improved by the same probiotics.



Reduction of chronic inflammation in humans

€↓pro-I TNF-alpha (> 9%)

$\textcircled{Q} \downarrow$ hsCRP, marker of chronic (low-level) inflammation (>5%)

⊕ ↑ Quality of life

DISCLAIMER: The statements made in this document have not been evaluated by local authority. The ingredients presented here are not intended to diagnose, treat, cure or prevent any disease. Please refer to local authority for any further information. PHOTO© Shutterstock, Roelmi HPC SynBalance MetSyn - rev 05 of 2019-08-27

HMG-CoA reductas